Astria Therapeutics, Inc. (ATXS)
NASDAQ: ATXS · Real-Time Price · USD
7.48
-0.10 (-1.26%)
Jan 22, 2025, 10:43 AM EST - Market open
Astria Therapeutics Employees
Astria Therapeutics had 59 employees as of December 31, 2023. The number of employees increased by 17 or 40.48% compared to the previous year.
Employees
59
Change (1Y)
17
Growth (1Y)
40.48%
Revenue / Employee
n/a
Profits / Employee
-$1,695,661
Market Cap
421.85M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
ATXS News
- 9 days ago - Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE - Business Wire
- 18 days ago - Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 6 weeks ago - Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE - Business Wire
- 6 weeks ago - Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis - Business Wire
- 2 months ago - Astria Therapeutics: Transformative Proof Of Concept Data In Hereditary Angioedema - Seeking Alpha
- 2 months ago - Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update - Business Wire
- 2 months ago - Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference - Business Wire
- 3 months ago - Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting - Business Wire